DP
RCUS icon

Diadema Partners’s Arcus Biosciences RCUS Stock Holding History

Diadema Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.14M Buy
+238,142
New +$5.14M 0.88% 38
2025
Q1 		– Sell
-165,965
Closed -$2.47M – 145
2024
Q4 		$2.47M Buy
+165,965
New +$2.71M 1.06% 30

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Diadema Partners's RCUS Position: Q1 2026 in Review

Diadema Partners opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 238,142 shares worth $5.14M. The stake represents 0.88% of the portfolio and ranks #38 among its holdings. This is a return to the name: Diadema Partners previously reported a position in RCUS as recently as Q4 2024.

Diadema Partners first reported a position in RCUS in Q4 2024 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Diadema Partners held 238,142 shares of Arcus Biosciences worth $5.14M as of Q1 2026.
  • Arcus Biosciences was a new Diadema Partners position in Q1 2026.
  • Arcus Biosciences made up 0.88% of Diadema Partners's portfolio in Q1 2026, its #38 holding.
  • Diadema Partners first reported a position in Arcus Biosciences in Q4 2024 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.